Homing of donor cells to a target zone in tissue using active therapeutics or substances

• US 20030129750A1
• Filed: 10/28/2002
• Published: 07/10/2003
• Est. Priority Date: 02/05/1998
• Status: Abandoned Application

• Current Assignee: Biosense, Inc. (Cardinal Health, Inc.)
• Original Assignee: Biosense, Inc. (Cardinal Health, Inc.)
• Inventors: Schwartz, Yitzhack
• Application Number:
  US10/281,753
• Publication Number:
  US 20030129750A1
• Time in Patent Office: Days
• US Class Current: 435/377
• CPC Class Codes: A61B 2017/00022 Sensing or detecting at the treatment site
• CPC Class Codes: A61B 2017/00243 cardiac
• CPC Class Codes: A61B 2017/00247 Making holes in the wall of the heart, e.g. laser Myocardial revascularization
• CPC Class Codes: A61B 2017/22082 after introduction of a substance
• CPC Class Codes: A61B 2018/00392 Transmyocardial revascularisation
• CPC Class Codes: A61B 2034/2051 Electromagnetic tracking systems
• CPC Class Codes: A61B 34/20 Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• CPC Class Codes: A61B 5/06 Devices, other than using radiation, for detecting or locating foreign bodies for removing same A61B17/50 ; determining position of probes within or on the body of the patient
• CPC Class Codes: A61B 5/062 using magnetic field
• CPC Class Codes: A61B 5/283 Invasive
• CPC Class Codes: A61B 5/417 the bone marrow
• CPC Class Codes: A61B 5/7285 for synchronising or triggering a physiological measurement or image acquisition with a physiological event or waveform, e.g. an ECG signal A61B6/5205, A61B6/541, A61B8/5207, A61B8/543 take precedence
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61M 2025/0076 Unidirectional valves
• CPC Class Codes: A61M 2025/0089 Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
• CPC Class Codes: A61M 2025/0166 Sensors, electrodes or the like for guiding the catheter to a target zone, e.g. image guided or magnetically guided
• CPC Class Codes: A61M 2210/125 Heart
• CPC Class Codes: A61M 25/0075 : Valve means
• CPC Class Codes: A61M 25/0082 : Catheter tip comprising a tool
• CPC Class Codes: A61M 25/0084 : being one or more injection needles
• CPC Class Codes: A61M 25/0105 : Steering means as part of the catheter or advancing means; Markers for positioning systems for detection of markers A61B
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for inducing vascular growth in tissue of a mammal comprises the steps of delivering a translocation stimulator such as a cytokine, chemokine or chemoattractant to a target zone of the tissue in the mammal and introducing donor precursor cells to the mammal in order to home the donor precursor cells to the target zone of the tissue for effecting vascular growth at the target zone.

Claims

1. A method for inducing vascular growth in tissue of a mammal, the method comprising the steps of:

(a) delivering a translocation stimulator to a target zone of the tissue in the mammal; and

(b) introducing donor precursor cells to the mammal for homing the donor precursor cells to the target zone of the tissue for effecting vascular growth at the target zone.

2. The method according to claim 1, further comprising using donor precursor cells that are endothelial progenitor cells.

3. The method according to claim 2, further comprising obtaining the endothelial progenitor cells from an allogeneic source.

4. The method according to claim 3, further comprising administering an immunosuppressive agent to the mammal.

5. The method according to claim 2, further comprising obtaining the endothelial progenitor cells from a xenogeneic source.

6. The method according to claim 5, further comprising administering an immunosuppressive agent to the mammal

7. The method according to claim 1, further comprising using donor precursor cells that are bone marrow derived stem cells.

8. The method according to claim 7, further comprising obtaining the bone marrow derived stem cells from an allogeneic source.

9. The method according to claim 8, further comprising administering an immunosuppressive agent to the mammal.

10. The method according to claim 7, further comprising obtaining the bone marrow derived stem cells from a xenogeneic source.

11. The method according to claim 10, further comprising administering an immunosuppressive agent to the mammal.

12. The method according to claim 1, further comprising genetically engineering the donor precursor cells to produce a therapeutic protein.

13. The method according to claim 1, further comprising delivering a translocation stimulator from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα

, TGFβ

, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα

, COX-2 and all isoforms and analogs thereof.

14. The method according to claim 1, further comprising delivering the translocation stimulator to the target zone of the tissue by injection.

15. The method according to claim 14, further comprising using a catheter for the injection of the translocation stimulator.

16. The method according to claim 15, further comprising navigating the catheter to the target zone using a position sensor on the catheter.

17. The method according to claim 15, further comprising injecting the translocation stimulator into the myocardium of the heart.

18. The method according to claim 15, further comprising injecting the translocation stimulator into the epicardium of the heart.

19. The method according to claim 15, further comprising injecting the translocation stimulator within a vessel of the heart.

20. The method according to claim 15, further comprising injecting the translocation stimulator into a wall of a vessel of the heart.

21. The method according to claim 1, further comprising identifying the target zone by mapping the tissue for viability.

22. The method according to claim 21, further comprising mapping the tissue for viability using a catheter having an electrode.

23. The method according to claim 22, further comprising navigating the catheter using a position sensor on the catheter.

24. The method according to claim 1, further comprising introducing the donor precursor cells by intravenous administration.

25. The method according to claim 1, further comprising introducing the donor precursor cells near the target zone of the tissue.

101. The method according to claim 22, further comprising mapping the tissue for viability in more than one chamber of the heart.

102. The method according to claim 101, further comprising conducting a bi-ventricular mapping procedure.

103. The method according to claim 101, further comprising mapping the tissue using a rapid mapping technique.

104. The method according to claim 103, further comprising creating a viability map using between six to ten points.

105. The method according to claim 104, further comprising creating the viability map with as few as three points.

106. The method according to claim 22, further comprising mapping the tissue using a rapid mapping technique.

107. The method according to claim 106, further comprising creating a viability map using between six to ten points.

108. The method according to claim 107, further comprising creating the viability map with as few as three points.

26. A method for inducing myogenesis in tissue of a mammal, the method comprising the steps of:

(a) slivering a translocation stimulator to a target zone of the tissue in the mammal; and

(b) introducing donor precursor cells to the mammal for homing the donor precursor cells the target zone of the tissue for effecting myogenesis at the target zone.

27. The method according to claim 26, further comprising using donor precursor cells that are endothelial progenitor cells.

28. The method according to claim 27, obtaining the endothelial progenitor cells from an allogeneic source.

29. The method according to claim 28, further comprising administering an immunosuppressive agent to the mammal.

30. The method according to claim 27, further comprising obtaining the endothelial progenitor cells from a xenogeneic source.

31. The method according to claim 30, further comprising administering an immunosuppressive agent to the mammal.

32. The method according to claim 26, further comprising using donor precursor cells that are bone marrow derived stem cells.

33. The method according to claim 32, further comprising obtaining the bone marrow derived stem cells from an allogeneic source.

34. The method according to claim 33, further comprising administering an immunosuppressive agent to the mammal.

35. The method according to claim 32, further comprising obtaining the bone marrow derived stem cells from a xenogeneic source.

36. The method according to claim 35, further comprising administering an immunosuppressive agent to the mammal.

37. The method according to claim 26, further comprising genetically engineering the donor precursor cells to produce a therapeutic protein.

38. The method according to claim 26, further comprising delivering at least one of the cytokines from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα

, TGFβ

, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα

, COX-2 and all isoforms and analogs thereof.

39. The method according to claim 26, further comprising delivering the translocation stimulator to the target zone of the tissue by injection.

40. The method according to claim 39, further comprising using a catheter for the injection of the translocation stimulator.

41. The method according to claim 40, further comprising navigating the catheter to the target zone using a position sensor on the catheter.

42. The method according to claim 40, further comprising injecting the translocation stimulator into the myocardium of the heart.

43. The method according to claim 40, further comprising injecting the translocation stimulator into the epicardium of the heart.

44. The method according to claim 40, further comprising injecting the translocation within a vessel of the heart.

45. The method according to claim 40, further comprising injecting the translocation stimulator into a wall of a vessel of the heart.

46. The method according to claim 26, further comprising identifying the target zone by mapping the tissue for viability.

47. The method according to claim 46, further comprising mapping the tissue for viability using a catheter having an electrode.

48. The method according to claim 47, further comprising navigating the catheter using a position sensor on the catheter.

49. The method according to claim 26, further comprising introducing the donor precursor cells by intravenous administration.

50. The method according to claim 26, further comprising introducing the donor precursor cells near the target zone of the tissue.

109. The method according to claim 47, further comprising mapping the tissue for viability in more than one chamber of the heart.

110. The method according to claim 109, further comprising conducting a bi-ventricular mapping procedure.

111. The method according to claim 109, further comprising mapping the tissue using a rapid mapping technique.

112. The method according to claim 111, further comprising creating a viability map using between six to ten points.

113. The method according to claim 112, further comprising creating the viability map with as few as three points.

114. The method according to claim 47, further comprising mapping the tissue using a rapid mapping technique.

115. The method according to claim 114 further comprising creating a viability map using between six to ten points.

116. The method according to claim 115, further comprising creating the viability map with as few as three points.

51. A method for inducing remodeling in tissue of a mammal, the method comprising the steps of:

(a) delivering a translocation stimulator to a target zone of the tissue in the mammal; and

(b) introducing donor precursor cells to the mammal for homing the donor precursor cells to the target zone of the tissue for effecting remodeling of the tissue at the target zone.

52. The method according to claim 51, further comprising using donor precursor cells that are endothelial progenitor cells.

53. The method according to claim 52, obtaining the endothelial progenitor cells from an allogeneic source.

54. The method according to claim 53, further comprising administering an immunosuppressive agent to the mammal.

55. The method according to claim 52, further comprising obtaining the endothelial progenitor cells from a xenogeneic source.

56. The method according to claim 55, further comprising administering an immunosuppressive agent to the mammal.

57. The method according to claim 51, further comprising using donor precursor cells that are bone marrow derived stem cells.

58. The method according to claim 57, further comprising obtaining the bone marrow derived stem cells from an allogeneic source.

59. The method according to claim 58, further comprising administering an immunosuppressive agent to the mammal.

60. The method according to claim 57, further comprising obtaining the bone marrow derived stem cells from a xenogeneic source.

61. The method according to claim 60, further comprising administering an immunosuppressive agent to the mammal.

62. The method according to claim 51, further comprising genetically engineering the donor precursor cells to produce a therapeutic protein.

63. The method according to claim 51, further comprising delivering at least one of the cytokines from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα

, TGFβ

, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα

, COX-2 and all isoforms and analogs thereof.

64. The method according to claim 51, further comprising delivering the translocation stimulator to the target zone of the tissue by injection.

65. The method according to claim 64, further comprising using a catheter for the injection of the translocation stimulator.

66. The method according to claim 65, further comprising navigating the catheter to the target zone using a position sensor on the catheter.

67. The method according to claim 65, further comprising injecting the translocation stimulator into the myocardium of the heart.

68. The method according to claim 65, further comprising injecting the translocation stimulator into the epicardium of the heart.

69. The method according to claim 65, further comprising injecting the translocation stimulator within a vessel of the heart.

70. The method according to claim 65, further comprising injecting the translocation stimulator into a wall of a vessel of the heart.

71. The method according to claim 51, further comprising identifying the target zone by mapping the tissue for viability.

72. The method according to claim 71, further comprising mapping the tissue for viability using a catheter having an electrode.

73. The method according to claim 72, further comprising navigating the catheter using a position sensor on the catheter.

74. The method according to claim 51, further comprising introducing the donor precursor cells by intravenous administration.

75. The method according to claim 51, further comprising introducing the donor precursor cells near the target zone of the tissue.

117. The method according to claim 72, further comprising mapping the tissue for viability in more than one chamber of the heart.

118. The method according to claim 117, further comprising conducting a bi-ventricular mapping procedure.

119. The method according to claim 117, further comprising mapping the tissue using a rapid mapping technique.

120. The method according to claim 119, further comprising creating a viability map using between six to ten points.

121. The method according to claim 120, further comprising creating the viability map with as few as three points.

122. The method according to claim 72, further comprising mapping the tissue using a rapid mapping technique.

123. The method according to claim 122, further comprising creating a viability map using between six to ten points.

124. The method according to claim 123, further comprising creating the viability map with as few as three points.

76. A method for inducing replacement of a scar in tissue of a mammal, the method comprising the steps of:

(a) establishing the scar as a target zone;

(b) delivering a translocation stimulator to the target zone of the tissue in the mammal; and

(c) introducing donor precursor cells to the mammal for homing the donor precursor cells to the target zone of the tissue for effecting replacement of the scar at the target zone.

77. The method according to claim 76, further comprising using donor precursor cells that are endothelial progenitor cells.

78. The method according to claim 77, obtaining endothelial progenitor cells from an allogeneic source.

79. The method according to claim 78, further comprising administering an immunosuppressive agent to the mammal.

80. The method according to claim 77, further comprising obtaining the endothelial progenitor cells from a xenogeneic source.

81. The method according to claim 80, further comprising administering an immunosuppressive agent to the mammal.

82. The method according to claim 76, further comprising using donor precursor cells that are bone marrow derived stem cells.

83. The method according to claim 82, further comprising obtaining the bone marrow derived stem cells from an allogeneic source.

84. The method according to claim 83, further comprising administering an immunosuppressive agent to the mammal.

85. The method according to claim 82, further comprising obtaining the bone marrow derived stem cells from a xenogeneic source.

86. The method according to claim 85, further comprising administering an immunosuppressive agent to the mammal.

87. The method according to claim 76, further comprising genetically engineering the donor precursor cells to produce a therapeutic protein.

88. The method according to claim 76, further comprising delivering at least one of the cytokines from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα

, TGFβ

, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα

, COX-2 and all isoforms and analogs thereof.

89. The method according to claim 76, further comprising delivering the translocation stimulator to the target zone of the tissue by injection.

90. The method according to claim 89, further comprising using a catheter for the injection of the translocation stimulator.

91. The method according to claim 90, further comprising navigating the catheter to the target zone using a position sensor on the catheter.

92. The method according to claim 90, further comprising injecting the translocation stimulator into the myocardium of the heart.

93. The method according to claim 90, further comprising injecting the translocation stimulator into the epicardium of the heart.

94. The method according to claim 90, further comprising injecting the translocation stimulator within a vessel of the heart.

95. The method according to claim 90, further comprising injecting the translocation stimulator into a wall of a vessel of the heart.

96. The method according to claim 76, further comprising identifying the target zone by mapping the tissue for viability.

97. The method according to claim 96, further comprising mapping the tissue for viability using a catheter having an electrode.

98. The method according to claim 97, further comprising navigating the catheter using a position sensor on the catheter.

99. The method according to claim 76, further comprising introducing the donor precursor cells by intravenous administration.

100. The method according to claim 76, further comprising introducing the donor precursor cells near the target zone of the tissue.

125. The method according to claim 97, further comprising mapping the tissue for viability in more than one chamber of the heart.

126. The method according to claim 125, further comprising conducting a bi-ventricular mapping procedure.

127. The method according to claim 126, further comprising mapping the tissue using a rapid mapping technique.

128. The method according to claim 127, further comprising creating a viability map using between six to ten points.

129. The method according to claim 128, further comprising creating the viability map with as few as three points.

130. The method according to claim 97, further comprising mapping the tissue using a rapid mapping technique.

131. The method according to claim 130, further comprising creating a viability map using between six to ten points.

132. The method according to claim 131, further comprising creating the viability map with as few as three points.